Abstract
Mycobacterium avium complex disease is the third most common opportunistic disease affecting patients with AIDS. In a nationwide survey, it occurred in 22 percent of such patients1; only Pneumocystis carinii pneumonia and Kaposi's sarcoma were more frequent, occurring in 58 percent and 28 percent of patients, respectively. M. avium disease is associated with debilitating symptoms and shortened survival.2 Thus, the reports in this issue of the Journal that document improved regimens for the prevention3,4 and treatment5 of this disease are welcome news.Clarithromycin and azithromycin both have good in vitro activity against M. avium, and it is . . .

This publication has 10 references indexed in Scilit: